FGF23 and myelodysplastic syndrome: Myelodysplastic neoplasms (MDS), hematopoietic stem cell disorders characterized by ineffective hematopoiesis and bone fragility, also exhibit elevated serum FGF-23 levels in both patients and mouse models.